Matthew Dennis

Johnson & Johnson on Monday announced an agreement to acquire Intra-Cellular Therapies for $132 per share in cash, or a total equity value of

Moderna's shares plunged as much as 24% on Monday after the company downgraded the top and bottom end of its sales outlook for the current year by $1 billion.

Eli Lilly said Tuesday that it expects full-year revenue from 2024 to be about $400 million short of its prior estimate, as the market for incretin-based drugs grew at a slower pace than anticipated.

OS Therapies plans to talk to the FDA about an accelerated approval pathway for OST-HER2 after the HER2-targeted immunotherapy candidate met the

Novartis won a temporary reprieve from generic competition to Entresto (sacubitril/valsartan) in the US, just days after a key patent on the blockbuster heart failure drug was upheld.

A higher dose of Novo Nordisk's semaglutide led to greater weight loss than the currently-approved dose level — sold as Wegovy — in adults with obesity.

AstraZeneca has replaced its general manager in China as it looks to recover from an ongoing probe into a number of current and former company employees.

Junshi Biosciences has snagged another partner for its PD-1 inhibitor Loqtorzi (toripalimab), this time bringing LEO Pharma onboard to commercialise the cancer therapy in Europe.

Atara Biotherapeutics said Tuesday that the FDA placed a hold on its two clinical programmes due to the same manufacturing issue that led to the recent rejection of a marketing application by the agency.

Sales of Johnson & Johnson's Darzalex jumped 20.9% in the fourth quarter of last year to $3.1 billion, helping the product take over the crown of the company's top selling drug.